Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma.

@article{Peest1995LowdoseRI,
  title={Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma.},
  author={Dietrich Peest and Regine Leo and S Bloche and R{\"u}diger Hein and S. Stannat-Kie\ssling and B Tschechne and Werner Fett and Peter J Harms and Lothar Hoffmann and Reiner Bartl},
  journal={British journal of haematology},
  year={1995},
  volume={89 2},
  pages={328-37}
}
In vitro data have demonstrated autologous T-lymphocytes with anti-tumour activity in multiple myeloma (MM). Therefore a phase I/II trial was conducted to study the feasibility, the effect on several immunological parameters, and the tumour response induction of low-dose recombinant interleukin-2 (rIL-2) in MM patients. 18 MM patients of advanced stages in… CONTINUE READING